Evotec DNA Damage Response Spin-Out Aims For First IND-Ready Drug In 2022

 
• By Sten Stovall
  
Spin off
Breakpoint Therapeutics will develop DDR therapies discovered internally by Evotec • Source: Shutterstock

More from Business

More from Scrip